DEA Plays Chemical Whack-A-Mole With Designer Drug CUMYL-PEGACLONE
Published Date: 12/11/2025
Proposed Rule
Summary
The Drug Enforcement Administration wants to make the temporary ban on CUMYL-PEGACLONE permanent by placing it in Schedule I, meaning it’s considered very risky and illegal to handle without special permission. This affects anyone who makes, sells, studies, or possesses this substance. Comments and hearing requests are open until January 12, 2026, so speak up before then!
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
Unauthorized handling may bring penalties
The proposal says any activity with CUMYL-PEGACLONE that is not authorized under the Controlled Substances Act would be unlawful and may subject the person to administrative, civil, and/or criminal sanctions under Schedule I rules.
CUMYL-PEGACLONE moved to Schedule I
The Drug Enforcement Administration proposes to permanently place CUMYL-PEGACLONE (also called SGT-151) in Schedule I, making permanent the temporary controls first ordered on December 12, 2023. If finalized, anyone who manufactures, distributes, imports, exports, researches, or possesses this substance would be subject to the regulatory controls for Schedule I substances; comments are due January 12, 2026.
Required registrations, security, and controls
If finalized, anyone handling CUMYL-PEGACLONE must follow Schedule I requirements: register with DEA, meet Schedule I security rules, use specified labeling and packaging, comply with manufacturing quotas, keep initial and biennial inventories, maintain records and reports, use required order forms, and follow import/export controls.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
Previous / Next Documents
Previous: 2025-22490, Guidance on Response Programs for Unauthorized Access to Member Information and Member Notice
The National Credit Union Administration (NCUA) is updating how it shares rules about handling unauthorized access to member info. Instead of keeping detailed guidance in the official rulebook, they’ll publish it separately to make updates easier and reduce confusion for credit unions. This change affects federally insured credit unions and invites public comments until February 9, 2026, with no new costs involved.
Next: 2025-22499, Establishment of Class E Airspace; Providence Seaside Hospital Heliport, Seaside, OR
The FAA is planning to create new Class E airspace around Providence Seaside Hospital Heliport in Seaside, Oregon, starting 700 feet above the ground. This change helps pilots safely use GPS-based flight paths for takeoffs and landings, making helicopter flights smoother and safer. If you want to share your thoughts, make sure to comment by January 26, 2026—no costs or fees involved!